Yvonne Greenstreet Sells 9,577 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the transaction, the chief executive officer owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Yvonne Greenstreet also recently made the following trade(s):

• On Thursday, November 13th, Yvonne Greenstreet sold 10,000 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $451.27, for a total value of $4,512,700.00.
• On Wednesday, November 12th, Yvonne Greenstreet sold 15,650 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.69, for a total value of $7,100,248.50.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $359.18 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a market capitalization of $47.45 billion, a price-to-earnings ratio of 1,496.56 and a beta of 0.32. The business has a 50 day simple moving average of $420.41 and a 200 day simple moving average of $421.12.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Analysts maintain a generally constructive stance: ALNY carries a consensus “Moderate Buy” from sell‑side firms, supporting a bullish medium‑term view for the shares. Alnylam Pharmaceuticals, Inc. Receives Consensus Rating of “Moderate Buy” from Analysts
• Positive Sentiment: Needham published a bullish forecast, highlighting upside tied to Alnylam’s longer‑term (Alnylam 2030) growth plan — a catalyst that could support recovery if execution meets targets. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: Context/valuation pieces are circulating that reassess ALNY’s premium valuation versus the newly unveiled Alnylam 2030 plan — useful for investors weighing long‑range upside against current multiples. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: Analyst opinions are mixed across the healthcare coverage universe, with some firms trimming targets while others remain upbeat — this divergence contributes to higher intraday volatility. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) …
• Negative Sentiment: Concentrated insider selling: multiple senior executives — including CEO Yvonne Greenstreet and several EVPs — disclosed sizable share sales on Jan. 12–13 (individual sales in the $0.5M–$3.5M range), which typically increases near‑term sell pressure and raises investor caution. Alnylam Insiders Quietly Unload a Major Chunk of Stock in Synchronized Sell‑Off
• Negative Sentiment: Market reaction to the company’s ambitious 2026 guidance and the Alnylam 2030 plan was negative — coverage noted a sharp intraday slide after the announcement — and Bank of America issued a pessimistic forecast that may amplify selling pressure. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Bank of America lowered its outlook and flagged downside risk, adding to analyst‑driven selling pressure following the company’s strategic/guidance update. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALNY. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after buying an additional 268,313 shares in the last quarter. Capital Research Global Investors boosted its stake in shares of Alnylam Pharmaceuticals by 0.4% during the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after acquiring an additional 31,184 shares in the last quarter. Groupama Asset Managment grew its holdings in shares of Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after purchasing an additional 75,936 shares during the period. Finally, Orbis Allan Gray Ltd lifted its holdings in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Leerink Partners reduced their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a report on Monday, December 15th. Raymond James Financial reaffirmed an “outperform” rating and issued a $472.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. Morgan Stanley increased their price objective on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a report on Monday, October 6th. Wells Fargo & Company boosted their target price on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Finally, Royal Bank Of Canada upped their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. Twenty-two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $490.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.